Detalles de la búsqueda
1.
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Eur J Nucl Med Mol Imaging
; 48(1): 113-122, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32383093
2.
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Eur J Nucl Med Mol Imaging
; 47(3): 695-712, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776632
3.
Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Eur J Nucl Med Mol Imaging
; 47(3): 740, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31863137
4.
68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
Eur J Nucl Med Mol Imaging
; 44(6): 941-949, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28138747
5.
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Eur J Nucl Med Mol Imaging
; 44(10): 1647-1655, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28589253
6.
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
J Nucl Med
; 63(3): 376-383, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34215673
7.
Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy.
Ann Nucl Med
; 32(7): 499-502, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29797003
Resultados
1 -
7
de 7
1
Próxima >
>>